Abiomed Pumps Cash Into Eleventh-Hour Bid For Thermo CardioSystems
This article was originally published in The Gray Sheet
Executive Summary
Abiomed may be able to leverage its strength in the capital markets - specifically, an enhanced cash position resulting from a $95 mil. secondary offering last March - to undercut a previously announced all-stock bid by Thoratec for ventricular assist device developer Thermo CardioSystems.
You may also be interested in...
Cryopreservation Study Points The Way To Future Skin Indications For Ortec
Ortec International will submit results of an equivalence study to FDA demonstrating that its OrCel composite cultured skin (CCS) continues to effectively heal wounds after prolonged cryopreservation.
Cryopreservation Study Points The Way To Future Skin Indications For Ortec
Ortec International will submit results of an equivalence study to FDA demonstrating that its OrCel composite cultured skin (CCS) continues to effectively heal wounds after prolonged cryopreservation.
AbioCor Artificial Heart Provides Safety Valve For Increased LVAD Demand
AbioMed's AbioCor artificial heart could stimulate demand for left ventricular assist devices (LVADs) by providing a back-up option for patients who fail treatment with the devices.